Novo Holdings portfolio company ReViral to be acquired by Pfizer
Novo Holdings’ portfolio company ReViral Ltd (ReViral) is to be acquired by Pfizer for up to USD525 million in total deal value. Founded in 2011, ReViral is a London, UK and Research Triangle Park, North Carolina based privately held clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising novel antiviral